Quantum-Si (QSI) Q2 Revenue Falls 47%
Quantum-Si ( NASDAQ:QSI ) , a developer of next-generation protein sequencing technology, reported its Q2 2025 earnings on August 5, 2025. The most significant news was a steep revenue shortfall, as GAAP sales came in at $0.59 million compared to analyst estimates of $1.11 million-a miss of ...
How this was made

The 30-second read
Why it matters
The revenue shortfall indicates operational or market challenges, which could lead to stock price correction. However, the company's innovative potential might attract investor interest despite short-term setbacks.
Market read
Limited immediate market impact but noteworthy for biotech sector investors; the company's performance could influence sector sentiment.
What to watch
Potential upcoming product launches or partnerships not yet reflected in the earnings report could provide upside surprises.
Background
Quantum-Si develops next-generation protein sequencing technology, aiming to revolutionize biotech research and diagnostics.
Ticker impact
The news reports a significant revenue shortfall for Quantum-Si, a developer of protein sequencing technology, which may impact its stock performance.
Moderate decline in stock price over the next 1-2 weeks, with potential for increased volatility.
The revenue shortfall is significant and may lead to investor concern, but the stock's somewhat-bullish sentiment score (17.75%) indicates mixed investor reactions and some buying interest.
Market effects
The biotech and biotech equipment sectors may experience slight negative sentiment due to the revenue decline of a tech developer in the protein sequencing space.
Limited regional impact; primarily affects US-based biotech sector.
Minimal; the company is a smaller player with limited global market influence.
Counterpoint
The revenue miss may be a short-term anomaly; the company's long-term prospects could remain intact if revenue decline is due to temporary factors.
Key entities
- CompanyQuantum-Si
Developer of protein sequencing technology.




